These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 23783141)
1. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. Wang M; Liu ZM; Li XC; Yao YT; Yin ZX J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141 [TBL] [Abstract][Full Text] [Related]
2. Concurrent blockade of NF-κB and Akt pathways potentiates cisplatin's antitumor activity in vivo. Sun H; Zheng X; Wang Q; Yan J; Li D; Zhou Y; Lin Y; Zhang L; Wang X Anticancer Drugs; 2012 Nov; 23(10):1039-46. PubMed ID: 22760211 [TBL] [Abstract][Full Text] [Related]
3. Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity. He HN; Wang X; Zheng XL; Sun H; Shi XW; Zhong YJ; Huang B; Yang L; Li JK; Liao LC; Zhang L; Hu LN; Lin Y Cancer Lett; 2010 Sep; 295(1):38-43. PubMed ID: 20207071 [TBL] [Abstract][Full Text] [Related]
4. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Lee MW; Kim DS; Min NY; Kim HT Int J Cancer; 2008 May; 122(10):2380-4. PubMed ID: 18224693 [TBL] [Abstract][Full Text] [Related]
5. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells. Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628 [TBL] [Abstract][Full Text] [Related]
6. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells. Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357 [TBL] [Abstract][Full Text] [Related]
7. Resveratrol Enhances Etoposide-Induced Cytotoxicity through Down-Regulating ERK1/2 and AKT-Mediated X-ray Repair Cross-Complement Group 1 (XRCC1) Protein Expression in Human Non-Small-Cell Lung Cancer Cells. Ko JC; Syu JJ; Chen JC; Wang TJ; Chang PY; Chen CY; Jian YT; Jian YJ; Lin YW Basic Clin Pharmacol Toxicol; 2015 Dec; 117(6):383-91. PubMed ID: 26046675 [TBL] [Abstract][Full Text] [Related]
8. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt. Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251 [TBL] [Abstract][Full Text] [Related]
9. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling. Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094 [TBL] [Abstract][Full Text] [Related]
10. NBM-T-BMX-OS01, an Osthole Derivative, Sensitizes Human Lung Cancer A549 Cells to Cisplatin through AMPK-Dependent Inhibition of ERK and Akt Pathway. Chen TJ; Zhou YF; Ning JJ; Yang T; Ren H; Li Y; Zhang S; Chen MW Cell Physiol Biochem; 2015; 36(3):893-906. PubMed ID: 26065336 [TBL] [Abstract][Full Text] [Related]
11. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M; Bai T; Tsang BK Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180 [TBL] [Abstract][Full Text] [Related]
12. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells. Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683 [TBL] [Abstract][Full Text] [Related]
13. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation. Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221 [TBL] [Abstract][Full Text] [Related]
14. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells. Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer. Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642 [TBL] [Abstract][Full Text] [Related]
16. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells. Su YJ; Tsai MS; Kuo YH; Chiu YF; Cheng CM; Lin ST; Lin YW Mol Pharmacol; 2010 Apr; 77(4):633-43. PubMed ID: 20042515 [TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells. Wong JC; Bathina M; Fiscus RR J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515 [TBL] [Abstract][Full Text] [Related]
18. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells. Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782 [TBL] [Abstract][Full Text] [Related]
19. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2. Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992 [TBL] [Abstract][Full Text] [Related]
20. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells. Tung CL; Jian YJ; Syu JJ; Wang TJ; Chang PY; Chen CY; Jian YT; Lin YW Exp Cell Res; 2015 May; 334(1):126-35. PubMed ID: 25662161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]